Article PDF first page preview

First page of Utility of cardiac biomarkers (NT-proBNP and Hs-Troponin-T) in predicting mortality, cardiovascular and renal outcomes in patients with chronic kidney disease

Introduction: Cardiac biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin-T (Hs-cTnT) are good prognostic indicators of long-term clinical cardiovascular outcomes in patients with chronic kidney disease. However, the clinical utility of combined biomarkers in predicting death and cardio-renal outcomes in patients with CKD remains unclear. This study examined the prognostic accuracy and incremental value of, NT-proBNP and Hs-cTnT for all-cause mortality, major adverse cardiovascular events (MACE), and end-stage kidney disease (ESKD) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients. Methods: Data from 1946 individuals with NDD-CKD prospectively included in the Salford Kidney Study was used to investigate the associations between NT-proBNP and Hs-cTnT with study endpoints. Hazards ratio or sub-hazards ratio and 95% confidence intervals (95%CI) were estimated using multivariate Cox-regression and competing risk models. The discriminatory power of NT-proBNP and Hs-cTnT along with kidney biomarkers (RBMs: eGFR and UACR) and Framingham Risk score (FRS) were calculated using Harrell’s C-index. Endpoint-specific risk scores were generated using regression coefficients obtained in a training dataset and confirmed in a validation one. Results: During median follow-up of 71.5 months, 931 (47.8%) deaths, 553 (28.4%) MACE and 554 (28.5%) ESKD events occurred. Baseline NT-proBNP and Hs-cTnT elevations were associated with significant increased risk of mortality, MACE and ESKD independently of FRS and RBMs. Combining NT-proBNP, Hs-cTnT, and FRS yielded the highest prognostic accuracy for all-cause mortality and MACE (respective C-statistics:0.713; 95%CI:0.695-0.731, and 0.697;95%CI:0.673-0.721,), while combining NT-proBNP, and Hs-cTnT with RBMs performed best at predicting ESKD (C-statistics:0.821; 95%CI: 0.786-0.826). Conclusions: In NDD-CKD patients, NT-proBNP and Hs-cTnT are predictors of all-cause mortality, MACE, and ESKD, independently of RBMs. Combining NT-proBNP and Hs-cTnT with RBMs outperformed risk prediction for ESKD compared to RBMs used alone or in combination.

Journal Section:
Patient-oriented, Translational Research
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution 4.0 International License .
Attribution